Repositorio Dspace

Assessment of Two Commercial Serological Assays for the Diagnosis and Post-Treatment Follow-Up of Strongyloidiasis in a Cohort of Patients with Chagas Disease

Mostrar el registro sencillo del ítem

dc.contributor.author Gil-Gallardo, Luis
dc.contributor.author Simón-Páez, Marina
dc.contributor.author Nieto-Martínez, Javier
dc.contributor.author Flores-Chávez, María-Delmans
dc.contributor.author Iborra-Bendicho, María-Asunción
dc.contributor.author Segovia-Hernández, Manuel
dc.date.accessioned 2026-09-17T12:15:36Z
dc.date.available 2026-09-17T12:15:36Z
dc.date.issued 2026-06-12
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28135
dc.description.abstract Strongyloidiasis is a neglected tropical disease that frequently coexists with Chagas disease (CD) among individuals from Latin America. Serology is increasingly used for the diagnosis and post-treatment follow-up of strongyloidiasis; however, comparative data on commercially available assays remain limited. We conducted a cross-sectional evaluation in a cohort of fifty-five patients with previously treated CD attending a Tropical Medicine Unit in Spain. All patients underwent serological screening for Strongyloides stercoralis using two commercial ELISA assays: the Strongyloides IgG ELISA kit (DRG Instruments GmbH) (DRG) and Anti-Strongyloides ELISA IgG (Euroimmun Medizinische Labordiagnostika AG) (Euroimmun). A composite reference standard defined infection as seropositivity in combination with eosinophil count (>0.5 × 10(3) eosinophils per µL) or seropositivity in both assays. Infected individuals received ivermectin and were reassessed one-year post-treatment. Thirty-seven patients (67.3%) met the criteria for strongyloidiasis. Concordance between the assays was substantial (? = 0.80). According to the composite study definition, both assays identified most patients as infected. At one-year follow-up, significant reductions were observed in DRG and Euroimmun indexes, as well as in eosinophil count (all p < 0.001). Treatment response rates were 83.3% with DRG and 73.3% with Euroimmun. Both ELISA assays showed comparable performance in identifying patients at risk of strongyloidiasis and in monitoring serological response after ivermectin treatment, supporting their usefulness in the management of patients with CD and suspected strongyloidiasis. Routine serological screening should be considered in this high-risk population.
dc.language.iso eng
dc.publisher MDPI
dc.rights Atribución/Reconocimiento 4.0 Internaciona
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.subject.mesh Humans
dc.subject.mesh Strongyloidiasis/diagnosis/drug therapy/parasitology
dc.subject.mesh Animals
dc.subject.mesh Female
dc.subject.mesh Enzyme-Linked Immunosorbent Assay/methods
dc.subject.mesh Strongyloides stercoralis/immunology
dc.subject.mesh Male
dc.subject.mesh Cross-Sectional Studies
dc.subject.mesh Chagas Disease/complications/drug therapy/parasitology
dc.subject.mesh Serologic Tests/methods
dc.subject.mesh Middle Aged
dc.subject.mesh Adult
dc.subject.mesh Antibodies, Helminth/blood
dc.subject.mesh Follow-Up Studies
dc.subject.mesh Immunoglobulin G/blood
dc.subject.mesh Spain
dc.subject.mesh Aged
dc.subject.mesh Ivermectin/therapeutic use
dc.title Assessment of Two Commercial Serological Assays for the Diagnosis and Post-Treatment Follow-Up of Strongyloidiasis in a Cohort of Patients with Chagas Disease
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 42347239
dc.relation.publisherversion https://www.mdpi.com/2076-0817/15/6/627
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.3390/pathogens15060627
dc.journal.title PATHOGENS
dc.identifier.essn 2076-0817


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internaciona Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internaciona

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta